You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《蓝筹业绩》中生制药(01177.HK)全年纯利27.71亿人币升0.3% 末期息2港仙
阿思达克 03-23 16:42
中国生物制药(01177.HK)公布截至去年12月底止全年业绩,营业额236.47亿元人民币(下同),按年跌2.4%。纯利27.71亿元,按年升0.3%;每股盈利14.74分。派末期息2港仙,连同已派发首三个季每季2港仙,全年合共派发股息8港仙。

期内,基本盈利约31.14亿元,按年轻微下降约0.3%;税前盈利为50.13亿元,下跌11.9%。研发总开支约28.53亿元,占集团收入约12.1%。

於去年,新产品销售占集团总收入约38.1%,达90.1亿元,按年上升约79.3%;抗肿瘤用药销售额约76.18亿元,按年上升约40.3%。

集团指,药品集中带量采购和范围不断扩大成为国内医药行业新常态,竞争激烈的仿制药利润空间也会因此受到显着影响,产业格局调整加快。集中采购降价後的低利润,以及医药代表备案管理後成本不断提高,难以继续支撑传统的处方药医院营销推广模式。基於网络平台的营销和服务模式在未来的医药营销中占据更重要地位,集团关注到这一趋势并已着手布局。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account